Targeted therapy
| Bevacizumab FDA-approved for this cancer. | — | Guideline option |
Immunotherapy
| Pembrolizumab FDA-approved for this cancer. | — | Guideline option |
Uterine Leiomyosarcoma: treatment map
Standard care plus compounds studied in the literature, organized by clinical readiness.
Treatment map: Uterine Leiomyosarcoma
Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.
12
Interventions
0
Standard of care
4
Tested in people
6
Lab / animal
0
Named in lit.
4
Classes
Tested in people, by trial phase: phase not reported ×4
Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Chemotherapy
—
—
1
1
—
Targeted therapy
—
1
3
—
—
Immunotherapy
—
1
—
1
—
Other
—
—
—
4
—
Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.
Established care — detail (2)
Investigational & adjunct compounds — detail (10)
Lab / animal only
"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.